title: Model for end-stage liver disease score in the first 3 weeks after liver transplantation as a predictor for long-term outcome.
abstract: BACKGROUND
  Early allograft dysfunction after liver transplantation (LTX) is not well defined. The aim of this study was to evaluate the value of early post-transplant model for end-stage liver disease (MELD) scores for predicting long-term outcome after transplantation.
  
  
  METHODS
  In this single-center retrospective study, 362 consecutive patients after LTX were included. MELD scores at 7, 14, and 21 postoperative days (PODs) were calculated from primary lab values. Receiver operating characteristic (ROC) analyses were carried out to determine the critical cutoff MELD scores for patient and graft survival.
  
  
  RESULTS
  One year after transplantation, the patient and graft survival rates were 85 and 69%, respectively. Although pretransplant MELD scores were similar, they were significantly different at POD7, POD14, and POD21 between patients who died and those who survived the first year after transplantation. As shown by ROC curves, for patient survival, the optimal time point is POD14 with a cutoff MELD of 17. At this time point, patients with a MELD below 17 showed a 1-year survival rate of 94.3% and patients with a MELD of 17 and higher showed a 1-year survival rate of only 75.4%. For graft survival, the optimal time point was day 7 and a cutoff MELD of 29 (92% at MELD<29; 56.4% at MELD≥29). A multivariate analysis of potential risk factors indicated a significant role of serum bilirubin and MELD score determined on POD14 for patient survival.
  
  
  CONCLUSIONS
  In conclusion, early postoperative MELD scores predict outcome after LTX. The postoperative MELD score at POD14 is a good predictor for patient survival and at POD7 for the graft survival after LTX.
authors.affiliation: Departments of aGeneral, Visceral, Transplantation, Vascular and Thoracic Surgery bMedicine 2 cAnesthesiology, University of Munich, Munich, Germany dScientific Center of Surgery, Baku, Azerbaijan.
authors.forename: Andrej
authors.initials: A
authors.lastname: Khandoga
authors.forename: Emil
authors.initials: E
authors.lastname: Iskandarov
authors.forename: Martin
authors.initials: M
authors.lastname: Angele
authors.forename: Alexander
authors.initials: A
authors.lastname: Gerbes
authors.forename: Lorenz
authors.initials: L
authors.lastname: Frey
authors.forename: Böyükkishi
authors.initials: B
authors.lastname: Ağayev
authors.forename: Karl-Walter
authors.initials: KW
authors.lastname: Jauch
authors.forename: Jens
authors.initials: J
authors.lastname: Werner
authors.forename: Markus
authors.initials: M
authors.lastname: Guba
mesh_terms: D000328:Adult; D000368:Aged; D019540:Area Under Curve; D016009:Chi-Square Distribution; D058625:End Stage Liver Disease / Q000175:diagnosis / Q000601:surgery*; D005260:Female; D005858:Germany; D006085:Graft Survival; D006801:Humans; D053208:Kaplan-Meier Estimate; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D055031:Primary Graft Dysfunction / Q000175:diagnosis / Q000209:etiology; D016016:Proportional Hazards Models; D012372:ROC Curve; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome